Public Health Emergency - Leading a Nation Prepared
Monoclonal antibodies (or mAbs) are a critical tool in fighting the COVID-19 pandemic, and the U.S. Department of Health and Human Services (HHS) is committed to fair and equitable access to these important products. A surge in the Delta variant coupled with low vaccination rates in certain areas of the country contributed to an increase in COVID-19 over the July-August timeframe.
As a result, the HHS Office of the Assistant Secretary for Preparedness and Response (HHS/ASPR) implemented a State and Territorial-Coordinated Distribution System for mAbs on Sep 13, 2021, similar to one that was in place from November 2020 to February 2021. Currently,
bamlanivimab/etesevimab are being distributed through this state/territory coordinated distribution system.
Step 1 HHS/ASPR
announces distributionquantities each
Step 2 State/territorial
allocate productadministration sites
Step 3 Administration
Step 4 Administration sites
report on product utilization
and stock on hand on
Wednesdays by 11:59 PM ET
Questions? If you have questions about the new state/territory coordinated distribution system, check out our frequently asked questions section.
View the FAQs >>
Home | Contact Us | Accessibility | Privacy Policies | Disclaimer | HHS Viewers & Players | HHS Plain Language
Assistant Secretary for Preparedness and Response (ASPR), 200 Independence Ave., SW, Washington, DC 20201
U.S. Department of Health and Human Services | USA.gov |
HealthCare.gov in Other Languages